In Vivo Efficacy and Toxicity Study (Real , Physical Lab Test No Literature or Simulated Data)

We have discovered a first-in-class small molecule inhibitor targeting GOT1 (Glutamic-Oxaloacetic Transaminase 1), which plays a key role in glutamine metabolism, NADPH homeostasis, and cancer cell survival, especially in pancreatic and colorectal cancers.

We are now seeking a qualified and experienced research partner to conduct a full in vivo proof-of-concept (POC) study, including efficacy and toxicity testing in mice.


Objectives of This Study:

1. Assess the anti-tumor efficacy of our GOT1 inhibitor in a relevant mouse cancer model.


2. Determine toxicity profile — including tolerability, weight change, and basic organ function data.


3. Deliver interpretable, high-quality data that can be included in a pitch to pharmaceutical companies.


Study Design Requirements:

Animal Model
- Rodent Type: Mice
- Strain: Athymic nude mice (or equivalent, as appropriate)
- Model Type: Pancreatic or colorectal cancer xenograft model (e.g., MIA PaCa-2, PANC-1, or HCT116)
- Tumors should be established subcutaneously, and treatment should begin when tumors reach measurable size.

Dosing
- Our molecule is orally bioavailable, so prefer oral dosing, unless IP (intraperitoneal) is more reliable.
- Provide at least two dosing groups (e.g., Low and High dose) + Vehicle Control.


⏱ Study Duration
- Standard treatment duration: 14–21 days
- Monitor tumor size every 2–3 days.
- Monitor body weight and behavior daily.


Endpoints & Deliverables:

Efficacy:
- Tumor volume graphs (with stats and p-values)
- Tumor inhibition percentage
- Tumor images at endpoint (optional but appreciated)

Toxicity:
-Body weight graph
-Clinical signs of toxicity (lethargy, diarrhea, posture)
-Serum analysis for liver and kidney function (AST, ALT, BUN, Creatinine) — if feasible


General:
-A detailed PDF or Word report summarizing:
-Methods
-Doses
-Results
-Interpretation
-Raw data in Excel (optional but ideal)

Confidentiality & Transparency
- This molecule is confidential. Please do not share any data or information publicly. We are open to an NDA if needed.


Budget
- We understand this is a highly skilled task, and we respect your time and resources. Our current budget is modest due to personal limitations. However, we’re not here to exploit anyone.

Promise:
- If your study leads to a successful deal with a pharmaceutical company (which we will inform you of), you will receive 10x the budget amount as a success bonus — no questions asked.
We’re loyal and believe in rewarding those who help us build something meaningful.

What We Expect From You
-Past experience with in vivo tumor models
-Professional, timely communication
- Honesty about what is possible and what is not